|
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
Results Show Treatment with Beloranib Resulted in Weight Loss and Corresponding Reductions in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects
|
Summary ToggleZafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
|
|
|
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
|
Summary ToggleZafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
|
|
|
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
|
Summary ToggleZafgen to Present at The Obesity Society 29th Annual Scientific Meeting
|
|
|
Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer
|
Summary ToggleZafgen Appoints Industry Executive Dennis Kim, M.D., M.B.A., to Chief Medical Officer
|
|
|
Summary ToggleZafgen Secures $33 Million Series C Financing
Proceeds to Advance Zafgen’s Lead Compound for Severe Obesity into Phase 2 Clinical Studies
|
Summary ToggleZafgen Secures $33 Million Series C Financing
|
|
|
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
Results Show MetAP2 Inhibitor Treatment Improves Cardiovascular Risk Markers in Severely Obese Subjects
Company Also Announces Initiation of Dose Escalation Trial in Obese Women
|
Summary ToggleZafgen Announces Cardiovascular Data from Phase 1b Study of ZGN-433 in Obesity at American Diabetes Association Annual Meeting
|
|
|
Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference
|
Summary ToggleZafgen to Present at BioCentury Future Leaders in the Biotech Industry Conference
|
|
|
Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
Findings Show MetAP2 Inhibition Treatment Drives Significant Weight Loss with Excellent Tolerability and Favorable Metabolic Effects
|
Summary ToggleZafgen Announces Positive Topline Phase 1b Data for ZGN-433 in Obesity
|
|
|
Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
Data Show Treatment with MetAP2 Inhibitor Eliminates Excess Body Fat through Regulation of Fat Metabolism and Food Intake and Normalizes Glucose Tolerance in Preclinical Models
|
Summary ToggleZafgen Presents Data on a New Class of Medicines to Treat Obesity at the American Diabetes Association Annual Meeting
|
|
|
Summary ToggleZafgen, Inc. to Present at Upcoming Conferences
|
Summary ToggleZafgen, Inc. to Present at Upcoming Conferences
|